Logo

FDA Recalls Over 67,000 Cases of Power Stick Deodorant Over Manufacturing Issues

In a sweeping recall, the FDA alongside A.P. Deauville has pulled more than 67,000 cases of Power Stick deodorants over manufacturing inconsistencies related to cGMP. The affected products, spanning multiple scents and roll-on varieties, were sold nationwide through major retailers. While no direct health hazards have been reported, experts emphasize the importance of compliance in safeguarding consumer confidence and safety.

FDA Recalls Over 67,000 Cases of Power Stick Deodorant Over Manufacturing Issues

FDA Initiates Major Recall on Power Stick Deodorants

In a significant consumer safety development, the U.S. Food and Drug Administration (FDA), alongside Easton, Pennsylvania-based brand A.P. Deauville, announced a voluntary recall affecting more than 67,000 cases of the popular Power Stick deodorant line. The announcement came on July 10, 2025, after the discovery of inconsistencies linked to the current Good Manufacturing Practices (cGMP), a critical set of quality standards manufacturing firms must follow.

Recall Details: Scope and Affected Products

The recall encompasses three specific Power Stick deodorant variants that had been distributed nationwide:

  • Power Stick for Her Roll-On Antiperspirant Deodorant (Power Fresh scent) – Over 21,200 cases
  • Power Stick Invisible Protection Roll-On Antiperspirant Deodorant (Spring Fresh scent) – Over 22,400 cases
  • Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant – More than 23,400 cases

While the recall notice did not disclose explicit safety hazards—such as contamination or harmful ingredients—it cited deviations from established manufacturing protocols. Such procedural lapses raise questions about the product's efficacy and, potentially, consumer safety.

Lot Numbers and Retail Availability

Consumers are urged to check the following lot numbers before usage:

  • Power Stick for Her Roll-On: 032026B011, 032226B031, 051626C241, 061526C882, 071226D371, 071226D381, 082526E341, 082826E402
  • Power Stick Invisible Protection Roll-On: 031726A991, 041226B561, 062026C901, 062026C911, 071026D351, 071026D361, 071326D391, 111626G231
  • Power Stick Original Nourishing Invisible Protection Roll-On: 101225D781, 032926B281, 032826B221, 041126B531, 062226D011, 070626D301, 070626D333, 111026G051, 111326G091, 111626G221

The products have been widely available through major retailers including Walmart, Dollar Tree, and Amazon, with pricing ranging from approximately $7 per three-pack to $30 for large multi-packs on discount sites. No official recall statement has yet been released by A.P. Deauville, adding an element of uncertainty regarding corrective measures and customer response.

Understanding cGMP and Its Importance

Compliance with current Good Manufacturing Practices (cGMP) is mandatory for all manufacturers of cosmetics and personal care goods in the United States. These standards ensure products are consistently produced and controlled according to quality norms to minimize risks related to contamination, improper labeling, or ingredient inconsistencies.

The FDA’s flagging of cGMP-related issues suggests that the facility responsible for producing these deodorants may have experienced lapses in quality control or documentation—problems that, while not always indicating a direct health threat, undermine consumer trust and product integrity.

Broader Context: Industry Implications and Consumer Safety

This recall highlights ongoing challenges in the personal care products industry, where demand for efficacy and safety often intersects with complex manufacturing chains. It underscores the need for vigilant regulatory oversight and transparent communication by manufacturers.

Industry experts note that while voluntary recalls reflect responsible corporate behavior, the lack of detailed explanations may leave consumers anxious. Additionally, online and big-box retailers’ vast supply chains can complicate swift removal of recalled items, increasing public exposure to potentially flawed products.

Consumers who own any deodorants matching the recalled lot numbers should immediately discontinue use and contact A.P. Deauville’s customer service, or their point of purchase, to inquire about refunds or replacements.

What Comes Next?

The incident invites deeper questions on how manufacturing compliance is monitored within the fragrance and personal care sectors. Especially amidst evolving regulatory requirements, there is a growing call for enhanced transparency and quicker public alerts when deviations arise.

For policy analysts and consumer advocates, the Power Stick recall serves as a case study emphasizing the essential balance between business interests and consumer protection.


Editor’s Note:

While no explicit safety hazard was confirmed, this broad recall of over 67,000 deodorant cases reminds us how even minor lapses in manufacturing protocols can have widespread repercussions. Consumers must remain vigilant about product lot numbers and manufacturers should prioritize transparency in communicating risks. This event prompts reflection on how personal care companies can bridge the gap between compliance, quality assurance, and consumer trust in a fast-moving market landscape.

World Elders Abuse Awareness Day Rally Highlights Senior Citizens’ Struggles
World Elders Abuse Awareness Day Rally Highlights Senior Citizens’ Struggles

On World Elders Abuse Awareness Day, Vizianagaram’s Senior Citizens Welfare Association organized a rally to highlight the growing challenges faced by elderly individuals, including verbal abuse, forced isolation, and insufficient healthcare support. Leaders urged the government to ensure dignity and comprehensive care for senior citizens.

Drone Attack on Sudan Hospital Kills Six Amid Ongoing Conflict
Drone Attack on Sudan Hospital Kills Six Amid Ongoing Conflict

A suspected drone attack conducted by paramilitary forces targeted Obeid International Hospital in North Kordofan, Sudan, resulting in six deaths and multiple injuries. The strike caused severe structural damage, forcing the hospital to cease operations. Occurring amid Sudan’s civil war between the military and Rapid Support Forces, the assault adds to a growing list of violent incidents destabilizing the region and exacerbating a dire humanitarian crisis.

Three Years Post-Roe Reversal: Majority of Americans Still Back Legal Abortion, Poll Shows
Three Years Post-Roe Reversal: Majority of Americans Still Back Legal Abortion, Poll Shows

Three years after the Supreme Court overturned Roe v. Wade, about 64% of Americans believe abortion should be legal in most or all cases. Despite aggressive state bans and sharp partisan divides, public support remains steady, particularly for abortions related to medical emergencies or fetal abnormalities. The evolving conversation now focuses on interstate access and telehealth, raising critical legal and ethical questions.

GLP-1 Drugs Show Promise for Women with Polycystic Ovary Syndrome (PCOS)
GLP-1 Drugs Show Promise for Women with Polycystic Ovary Syndrome (PCOS)

Millions of women with polycystic ovary syndrome (PCOS) often face years of frustrating symptoms with limited treatment options. Emerging evidence suggests that GLP-1 receptor agonists—medications originally developed for diabetes and obesity—may improve hormonal balance, menstrual regularity, and weight management in PCOS patients. Clinical trials and patient stories highlight significant benefits, though regulatory approval and insurance coverage remain barriers to widespread use. Experts call for more research to understand these drugs’ full potential in transforming PCOS care.

CDC Vaccine Advisory Panel Meets for First Time After New Appointments
CDC Vaccine Advisory Panel Meets for First Time After New Appointments

The Advisory Committee on Immunization Practices (ACIP) convened for the first time since the appointment of new members by Health and Human Services Secretary Robert F. Kennedy Jr., who replaced the entire panel with some vaccine critics. The group, which advises the CDC on vaccine policies, faces uncertainty over its future recommendations, particularly regarding COVID-19 and RSV vaccines. New chair Dr. Martin Kulldorff promotes an evidence-based approach amid the controversial shifts.

RFK Jr.’s Dismissal of CDC Vaccine Advisors Sparks Public Health Concerns
RFK Jr.’s Dismissal of CDC Vaccine Advisors Sparks Public Health Concerns

Health and Human Services Secretary Robert F. Kennedy Jr. has fired the entire Advisory Committee on Immunization Practices, a move alarming public health experts who warn it threatens vaccine oversight and public trust. The decision could lead to politicized vaccine recommendations and lower immunization rates amidst rising disease outbreaks. Experts call for transparency and caution as the U.S. navigates this critical shift.

Dr. Reddy’s Eyes Major Growth with Generic Weight-Loss Drug Rollout by 2026
Dr. Reddy’s Eyes Major Growth with Generic Weight-Loss Drug Rollout by 2026

With obesity and diabetes rates soaring worldwide, Dr. Reddy’s Laboratories is seizing a unique opportunity by introducing generic versions of semaglutide across emerging markets by 2026. This move could lower drug costs, expand access to effective therapies, and generate significant revenue, while challenging established pharmaceutical giants like Novo Nordisk and Eli Lilly. Experts highlight this as a pivotal moment for global health equity in chronic disease treatment.

Breakthrough Mouse Model Unveils Secrets of Smell Regeneration
Breakthrough Mouse Model Unveils Secrets of Smell Regeneration

A team at Tufts University has devised a simple 3D mouse model to study the regeneration of olfactory neurons. Contrary to past beliefs, certain dormant stem cells play active roles in repairing and generating nerve tissue linked to smell. The model also reflects age-related decline in neuron growth, paving the way for future treatments of smell loss.

White House Confirms Trump’s Chronic Venous Insufficiency Amid Concerns Over Swollen Legs
White House Confirms Trump’s Chronic Venous Insufficiency Amid Concerns Over Swollen Legs

Following public concern over President Trump's swollen ankles and bruised hands, the White House confirmed he has been diagnosed with chronic venous insufficiency, a common vein condition in older adults. Medical evaluations showed no heart failure or serious vascular issues, with experts emphasizing the normalcy yet importance of monitoring this vascular condition in aging leaders.

U.S. Removes Mercury Preservative from Flu Shots Amid Vaccine Debate
U.S. Removes Mercury Preservative from Flu Shots Amid Vaccine Debate

The Department of Health and Human Services announced it will eliminate the mercury-based preservative thimerosal from all flu vaccines in the U.S., a move propelled by vaccine panel recommendations and led by HHS Secretary Robert F. Kennedy Jr. While intended to reduce unnecessary mercury exposure, experts warn it may lower vaccination rates and fuel unproven fears linking thimerosal to developmental disorders. This decision highlights ongoing tensions between public health policy and vaccine skepticism in America.

White House Confirms President Trump’s Diagnosis of Chronic Venous Insufficiency
White House Confirms President Trump’s Diagnosis of Chronic Venous Insufficiency

President Donald Trump has been diagnosed with chronic venous insufficiency, a common vascular condition that causes leg swelling. The White House assured the public that thorough exams found no serious complications. This update aims to enhance transparency about the 79-year-old leader's health, amidst broader concerns about aging in political office. Aspirin-related bruising was also explained by the Press Secretary.

Is America Overlooking Deadlier Synthetic Opioids Beyond Fentanyl?
Is America Overlooking Deadlier Synthetic Opioids Beyond Fentanyl?

As the US ramps up efforts against fentanyl, a silent but deadlier synthetic opioid—nitazenes—is rapidly spreading. Originating from 1960s Switzerland, nitazenes are proving far more potent and difficult to detect, increasingly involved in overdoses. Experts warn that unless policymakers expand focus beyond fentanyl, the opioid epidemic may worsen, driven by evolving chemistry rather than crop supply. This article unpacks the complexities behind nitazenes’ rise and the urgent need for adaptive strategies.

Trump’s Drug Price Ultimatum Forces Pharma Firms into Swift Response
Trump’s Drug Price Ultimatum Forces Pharma Firms into Swift Response

President Donald Trump has issued a firm ultimatum to 17 leading pharmaceutical companies, demanding binding commitments to reduce U.S. drug prices to 'most favored nation' levels by September 29. This directive aims to tackle soaring prescription medicine costs by eliminating preferential pricing abroad and cutting out pharmacy middlemen. The move has unsettled healthcare stocks and sparked varied responses from industry leaders, some of whom acknowledge the need for price equalization. As the deadline nears, this development raises urgent questions about the balance between affordability and innovation in U.S. healthcare.

Bristol Myers Squibb and Pfizer Cut Eliquis Price by Over 40% for Direct Patient Sales
Bristol Myers Squibb and Pfizer Cut Eliquis Price by Over 40% for Direct Patient Sales

Pharma leaders Bristol Myers Squibb and Pfizer announce a new program selling their blood thinner Eliquis directly to certain patients at a 40% discount, bypassing insurers and middlemen. While offering relief to uninsured and underinsured patients, the move raises questions about drug affordability and systemic pricing disparities amid evolving U.S. healthcare policies.

FDA to Factor Drug Affordability in New Voucher Program Expediting Approvals
FDA to Factor Drug Affordability in New Voucher Program Expediting Approvals

In a move that could reshape drug approvals and pricing, the FDA announced it will factor in medication affordability when issuing new vouchers that speed up treatment reviews. This policy reflects mounting pressure to reduce high drug costs in the U.S. while maintaining innovation and safety. Experts caution about balancing speed with thorough evaluation and transparency in measuring affordability.

How Much Coffee Is Too Much? Experts Weigh In on Safe Daily Limits
How Much Coffee Is Too Much? Experts Weigh In on Safe Daily Limits

Coffee drinking is a daily ritual for millions, but how much is truly safe? Recent studies highlight that while one to three cups might bring health benefits, heavy consumption poses risks, especially for those with hypertension. Experts recommend keeping caffeine below 400 mg per day and listening to your body to avoid side effects like jitters or disrupted sleep. Personalized moderation remains essential in balancing the perks and pitfalls of caffeine.

Japan’s Crucial Upper House Election Tests Prime Minister Ishiba’s Leadership
Japan’s Crucial Upper House Election Tests Prime Minister Ishiba’s Leadership

Japanese voters head to the polls in a closely contested upper house election that could reshape the nation’s political landscape. Rising prices and immigration concerns are testing Prime Minister Shigeru Ishiba’s grip on power as his Liberal Democratic Party and coalition partner Komeito face possible losses. With half the seats in the 248-seat chamber contested and a critical US trade deal deadline approaching, the outcome threatens economic stability and policy direction. Experts warn of delicate post-election negotiations and potential shifts in Japan’s longstanding political order.

White House Eyes Federal Reserve HQ Inspection Amid Trump-Powell Tensions
White House Eyes Federal Reserve HQ Inspection Amid Trump-Powell Tensions

In the midst of a mounting feud between President Donald Trump and Federal Reserve Chair Jerome Powell, the White House is seeking an inspection of the Federal Reserve's $2.5 billion building renovations in Washington, D.C. This move reflects broader tensions over monetary policy decisions and institutional independence, raising critical questions about governance, economic stability, and political influence.